Cas:14288-91-6 4-amino-N-[4-(trifluoromethyl)pyrimidin-2-yl]benzenesulfonamide manufacturer & supplier

Chemical Name:4-amino-N-[4-(trifluoromethyl)pyrimidin-2-yl]benzenesulfonamide

CAS.NO:14288-91-6

Synonyms:4-amino-N-(4-trifluoromethyl-pyrimidin-2-yl)-benzenesulfonamide;4-trifluoromethyl-2-N-(4-aminophenylsulfo)aminopyrimidine;N1-<4-Trifluormethyl-2-pyrimidinyl>-sulfanilamid

Molecular Formula:C₁₁H₉F₃N₄O₂S

Molecular Weight:318.27500

HS Code:2935009090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:106.35000

Exact Mass:318.04000

LogP:3.61340

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-amino-N-(4-trifluoromethyl-pyrimidin-2-yl)-benzenesulfonamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,-sulfanilamid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Trifluormethyl-2-pyrimidinyl&gt Use and application,4-trifluoromethyl-2-N-(4-aminophenylsulfo)aminopyrimidine technical grade,usp/ep/jp grade.

Related News: Inceptua has global operations with local offices across Europe, USA, and Asia 4-amino-N-[4-(trifluoromethyl)pyrimidin-2-yl]benzenesulfonamide manufacturer China considers self-ruled Taiwan to be part of its territory and has long sought to limit its diplomatic relations and recognition at international bodies such as the W.H.O. 4-amino-N-[4-(trifluoromethyl)pyrimidin-2-yl]benzenesulfonamide supplier China considers self-ruled Taiwan to be part of its territory and has long sought to limit its diplomatic relations and recognition at international bodies such as the W.H.O. 4-amino-N-[4-(trifluoromethyl)pyrimidin-2-yl]benzenesulfonamide vendor Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2). 4-amino-N-[4-(trifluoromethyl)pyrimidin-2-yl]benzenesulfonamide factory The measure starts on February 4, according to South Korean Prime Minister Chung Sye-kyun.